Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

“Brexit has been a catalyst for UK clinical research… it’s turbocharged change”

The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?

- PMLiVE

GSK, J&J say monthly injection keeps HIV controlled

The once every four-week treatment could free those from taking daily pills

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

Boehringer’s IL-36-targeting drug tackles rare form of psoriasis

Antibody would be first-in-class

Roche - Basel

Roche files Venclexta plus Gazyva in CLL

Chemo-free combo assessed via FDA's Real-Time review

- PMLiVE

International Women’s Day – 8 March 2019

International Women's Day has been celebrated since its inception in 1911. But how far have we come?

Page & Page Health

Bedrock celebrate inspirational women

The company is keen to champion its women’s achievements

Bedrock Healthcare Communications

- PMLiVE

Changes at Oxford PharmaGenesis, Synergy Vision and akt health communications

The latest movers in healthcare comms

- PMLiVE

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

NHS England going public with price makes deal impossible, says Leiden

Bristol-Myers Squibb (BMS) building

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

- PMLiVE

Depression drug failure adds to Allergan’s woes

Axe hangs over remaining monotherapy and suicidality trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links